Findings

What do systematic reviews say?

2 questions · 4 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast cancer mortality: ≤ 50 years

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: ≤ 50 years compared with no RRSO (very low certainty).

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.78 [0.55, 1.09]
3 studies · 4566 participants
Very low
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.49 [0.08, 2.9]
2 studies · 444 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast cancer mortality: > 50 years

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: > 50 years compared with no RRSO (very low certainty).

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 1.27 [0.67, 2.38]
3 studies · 4566 participants
Very low
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 1.36 [0.68, 2.75]
2 studies · 444 participants
Very low